159 related articles for article (PubMed ID: 31215242)
1. The NAME trial: a direct comparison of classical oral Navelbine versus Metronomic Navelbine in metastatic breast cancer.
Langkjer ST; Kenholm J; Jensen JD; Wedervang K; Brixen AT; Grunnet M; Stenbygaard L; Gilje B; Danø H; Glavicic V; Jacobsen EH; Brems-Eskildsen AS; Kruse HL; Dongsgaard T; Neimann J; Geisler J
Future Oncol; 2019 Aug; 15(22):2561-2569. PubMed ID: 31215242
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
[TBL] [Abstract][Full Text] [Related]
3. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
4. Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer.
Huang L; Wang X; Zhou L; Di L; Zheng H; Jiang Z; Wang Y; Song X; Feng J; Yu S; Liu Y; Zheng H; Shen K; Tong Z; Shao Z
Cancer Chemother Pharmacol; 2020 Jan; 85(1):205-215. PubMed ID: 31838561
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.
Krajnak S; Decker T; Schollenberger L; Rosé C; Ruckes C; Fehm T; Thomssen C; Harbeck N; Schmidt M
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3391-3400. PubMed ID: 33743073
[TBL] [Abstract][Full Text] [Related]
6. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
7. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E; Palazzo A; Maisonneuve P; Cancello G; Iorfida M; Sciandivasci A; Esposito A; Cardillo A; Mazza M; Munzone E; Lai A; Goldhirsch A; Colleoni M
Cancer Lett; 2017 Aug; 400():276-281. PubMed ID: 28131905
[TBL] [Abstract][Full Text] [Related]
9. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.
Adamo B; Bellet M; Paré L; Pascual T; Vidal M; Pérez Fidalgo JA; Blanch S; Martinez N; Murillo L; Gómez-Pardo P; López-González A; Amillano K; Canes J; Galván P; González-Farré B; González X; Villagrasa P; Ciruelos E; Prat A
Breast Cancer Res; 2019 Sep; 21(1):108. PubMed ID: 31533777
[TBL] [Abstract][Full Text] [Related]
10. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.
De Iuliis F; Salerno G; Taglieri L; Lanza R; Scarpa S
Tumori; 2015; 101(1):30-5. PubMed ID: 25702645
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with vinorelbine (Navelbine) and mitoxantrone for metastatic breast cancer: a review.
Vogel CL
Semin Oncol; 1995 Apr; 22(2 Suppl 5):61-5. PubMed ID: 7740335
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists?
Cazzaniga ME; Munzone E; Montagna E; Pappagallo G
Expert Rev Anticancer Ther; 2018 Aug; 18(8):805-814. PubMed ID: 29902087
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Ibrahim NK; Valero V; Rahman Z; Theriault RL; Walters RS; Buzdar AU; Booser DJ; Holmes FA; Murray JL; Willey J; Bast R; Hortobagyi GN
Cancer Invest; 2001; 19(5):459-66. PubMed ID: 11458813
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
15. A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer.
Sanna G; Pestrin M; Moretti E; Biagioni C; De Santo I; Gabellini S; Galardi F; McCartney A; Biganzoli L
Clin Breast Cancer; 2021 Aug; 21(4):e332-e339. PubMed ID: 33353853
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Finek J; Holubec L; Svoboda T; Sefrhansova L; Pavlikova I; Votavova M; Sediva M; Filip S; Kozevnikova R; Kormunda S
Anticancer Res; 2009 Feb; 29(2):667-70. PubMed ID: 19331218
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience.
Bruno S; Puerto VL; Mickiewicz E; Hegg R; Texeira LC; Gaitan L; Martinez L; Fernandez O; Otero J; Kesselring G
Am J Clin Oncol; 1995 Oct; 18(5):392-6. PubMed ID: 7572754
[TBL] [Abstract][Full Text] [Related]
18. Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.
Saloustros E; Kalbakis K; Vardakis N; Kalykaki A; Milaki G; Rovithi M; Agelaki S; Saridaki Z; Georgoulias V; Mavroudis D
J BUON; 2011; 16(2):215-8. PubMed ID: 21766488
[TBL] [Abstract][Full Text] [Related]
19. Metronomic chemotherapy for advanced breast cancer patients.
Cazzaniga ME; Dionisio MR; Riva F
Cancer Lett; 2017 Aug; 400():252-258. PubMed ID: 28017894
[TBL] [Abstract][Full Text] [Related]
20. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
